Newsfeeds - Spark Newswire

1 minute read

Earnings

Earnings Outlook For Sabra Health Care REIT

Today, 9:51 AM

Sabra Health Care REIT (NASDAQ:SBRA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Sabra Health Care REIT will report an earnings per share (EPS) of $0.16.

SBRA

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For May 25, 2022

By Benzinga Insights

Today, 9:51 AM

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

ALE

1 minute read

Mizuho Upgrades Sabra Health Care REIT to Buy, Lowers Price Target to $15

By Benzinga Newsdesk

Today, 9:51 AM

Mizuho analyst Vikram Malhotra upgrades Sabra Health Care REIT (NASDAQ:SBRA) from Neutral to Buy and lowers the price target from $16 to $15.

SBRA

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 9:51 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 9:51 AM

Wednesday's session saw 784 companies set new 52-week lows.

AADI

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 9:51 AM

On Friday =, 431 companies hit new 52-week lows.

AAOI

15 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 9:51 AM

On Tuesday, 242 companies hit new 52-week lows.

ACRX

1 minute read

Barclays Downgrades Sabra Health Care REIT to Equal-Weight, Lowers Price Target to $14

By Benzinga Newsdesk

Today, 9:51 AM

Barclays analyst Steve Valiquette downgrades Sabra Health Care REIT (NASDAQ:SBRA) from Overweight to Equal-Weight and lowers the price target from $16 to $14.

SBRA

1 minute read

Credit Suisse Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $15

By Benzinga Newsdesk

Today, 9:51 AM

Credit Suisse analyst Omotayo Okusanya maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $14 to $15.

SBRA

1 minute read

Sabra Health Care REIT Q4 FFO $0.39 Down From $0.42 YoY, Sales $135.66M Miss $151.64M Estimate

By Benzinga Newsdesk

Today, 9:51 AM

Sabra Health Care REIT (NASDAQ:SBRA) reported quarterly earnings of $0.39 per share. This is a 7.14 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales

SBRA